Power up your LNP and AAV sample prep with Unagi
12 October 2022 | By Unchained Labs
Watch this on-demand webinar to see first-hand data results demonstrating the power and flexibility of Unagi for nucleic acids, LNPs and AAVs.
List view / Grid view
12 October 2022 | By Unchained Labs
Watch this on-demand webinar to see first-hand data results demonstrating the power and flexibility of Unagi for nucleic acids, LNPs and AAVs.
This whitepaper reviews the drug discovery progress for neurodegenerative diseases, focusing on promising candidates identified using iPSC technology.
Victoria Rees and Ria Kakkad from Drug Target Review bring you the key takeaways from the ELRIG Drug Discovery 2022 event in London.
A geometric deep-learning model is faster and more accurate than state-of-the-art computational models, reducing the chances and costs of drug trial failures.
Europe’s largest meeting for life sciences professionals is just around the corner – be a part of it. This year, Drug Discovery 2022 is coming to the ever-buzzing ExCel centre in London from 4-5 October and will focus on ‘driving the next life sciences revolution’ as we build new momentum…
Jiankun Lyu hopes to use algorithms to find improved drugs by screening chemicals that may look different to a protein’s known ligands but work in a similar way.
Using an AI algorithm that models drug and target protein interactions, researchers achieved up to 97 percent accuracy in identifying promising drug candidates.
Compendium of iQue® advanced flow cytometry platform application posters: Antibody discovery and immuno-oncology.
Discover how picodroplet microfluidic technologies can identify and isolate 'hit' cells, quantify varying concentrations of antigen-specific antibodies and much more.
Researchers have developed a new method that enables high-throughput screening of Huntington’s disease organoids.
In the search for a rapid, easy way to identify drugs to fight SARS-CoV-2, researchers from across the US came together to develop and apply a high-throughput ADP-ribosylhydrolase assay, ADPr-Glo. Here, Dr Veronica Busa and Dr Anthony Leung from Johns Hopkins University describe the ADPr-Glo assay and how it can be…
In this Q&A, Immunexpress Chief Executive Officer Dr Rolland Carlson and Chief Scientific Officer Dr Richard Brandon discuss key aspects for molecular diagnostic discovery and development platforms, including how to best leverage microarray and next-generation sequencing (NGS) tools.
Learn how R&D Systems™ Avi-tag biotinylated proteins can be used as an alternative to amine biotin coupling in surface plasmon resonance experiments.
Researchers have used a high-throughput assay to screen for potential small molecule SARS-CoV-2 replication inhibitors.
A report has shown that the immuno-oncology drug discovery outsourcing market is set to be worth $2563 million by 2030.